Published in Epigenetics on May 01, 2013
Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet (2014) 1.94
High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol (2015) 1.93
miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget (2015) 0.93
Choosing the right cell line for renal cell cancer research. Mol Cancer (2016) 0.82
The epigenetic landscape of renal cancer. Nat Rev Nephrol (2016) 0.81
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. Cold Spring Harb Perspect Med (2016) 0.81
ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy. Adv Cancer Res (2014) 0.80
Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model. Clin Epigenetics (2016) 0.80
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. Adv Cancer Res (2016) 0.78
Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer (2016) 0.77
Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma. Int J Mol Sci (2015) 0.76
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy. Epigenetics (2014) 0.76
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
The epigenomics of cancer. Cell (2007) 30.91
CpG islands in vertebrate genomes. J Mol Biol (1987) 23.16
DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet (2006) 18.08
Epigenetics in cancer. N Engl J Med (2008) 17.36
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol (1982) 8.47
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics (2009) 6.08
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene (2002) 5.96
Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res (2001) 5.89
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res (1998) 4.39
The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol (2010) 4.25
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A (1998) 3.90
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
DNA methylation: bisulphite modification and analysis. Nat Protoc (2006) 3.44
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res (1997) 3.34
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03
The UTX gene escapes X inactivation in mice and humans. Hum Mol Genet (1998) 2.91
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol (2002) 2.43
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res (1997) 1.95
Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene (1999) 1.75
Familial aggregation of abnormal methylation of parental alleles at the IGF2/H19 and IGF2R differentially methylated regions. Hum Mol Genet (2003) 1.68
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer (2004) 1.57
Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49
Comparative sequence and x-inactivation analyses of a domain of escape in human xp11.2 and the conserved segment in mouse. Genome Res (2004) 1.29
Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene (2003) 1.21
Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer (2007) 1.19
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat (2012) 1.06
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer (2007) 1.06
Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Clin Cancer Res (2008) 1.06
Evaluation of single CpG sites as proxies of CpG island methylation states at the genome scale. Nucleic Acids Res (2012) 0.98
Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett (2011) 0.83
Cancer. Emerging anatomy of the BAP1 tumor suppressor system. Science (2012) 0.82
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res (2004) 1.66
Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res (2004) 1.62
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59
Signaling pathways in renal cell carcinoma. Cancer Biol Ther (2010) 1.58
Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res (2004) 1.31
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res (2011) 1.29
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22
Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res (2007) 1.21
Promoter methylation and the detection of breast cancer. Cancer Causes Control (2009) 1.18
Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res (2003) 1.13
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res (2008) 1.11
LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer. J Biol Chem (2002) 1.10
Reduction of Pax9 gene dosage in an allelic series of mouse mutants causes hypodontia and oligodontia. Hum Mol Genet (2005) 1.09
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res (2013) 1.06
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) (2011) 1.03
VILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival. PLoS One (2008) 1.00
Reducing number entry errors: solving a widespread, serious problem. J R Soc Interface (2010) 1.00
DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. Cancer Epidemiol (2010) 0.98
Porcine intact and wounded skin responses to atmospheric nonthermal plasma. J Surg Res (2012) 0.96
The genetics of renal oncocytosis: a possible model for neoplastic progression. Cancer Genet Cytogenet (2004) 0.93
The effect of interruptions on postcompletion and other procedural errors: an account based on the activation-based goal memory model. J Exp Psychol Appl (2008) 0.92
Epigenetics of kidney cancer and bladder cancer. Epigenomics (2011) 0.91
Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol (2011) 0.89
Haploinsufficiency of the germ cell-specific nuclear RNA binding protein hnRNP G-T prevents functional spermatogenesis in the mouse. Hum Mol Genet (2008) 0.86
Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells. Cancer Biol Ther (2003) 0.84
Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett (2011) 0.83
Molecular genetics and histopathologic features of adult distal nephron tumors. Urology (2002) 0.82
Evaluating care pathways for community psychiatry in England: a qualitative study. J Eval Clin Pract (2012) 0.81
The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am (2003) 0.81
Genome-wide promoter methylome of small renal masses. PLoS One (2013) 0.80
Epigenomics-based diagnostics. Clin Chem (2010) 0.79
Characterization of starch from tubers of yam bean (Pachyrhizus ahipa). J Agric Food Chem (2002) 0.77
Synergistic interactions between the genetically modified bacterial polysaccharide P2 and carob or konjac mannan. Carbohydr Res (2004) 0.75